Loading...
XTAI
4133
Market cap60mUSD
Jun 13, Last price  
29.25TWD
1D
-0.51%
1Q
-1.68%
Jan 2017
-18.02%
IPO
-73.70%
Name

Abnova Taiwan Corp

Chart & Performance

D1W1MN
P/E
28.75
P/S
4.99
EPS
1.02
Div Yield, %
2.46%
Shrs. gr., 5y
0.58%
Rev. gr., 5y
-3.02%
Revenues
355m
-7.01%
402,834,000475,072,000472,569,000463,774,000463,699,000438,112,000451,367,000439,826,000475,073,000426,023,000414,158,000456,449,000451,487,000411,756,000382,052,000355,257,000
Net income
62m
+41.05%
99,558,000149,045,000119,865,00076,838,00072,896,00065,643,00044,911,00053,539,00058,966,00046,118,0003,263,00036,526,00028,369,00074,843,00043,678,00061,607,000
CFO
51m
-33.28%
63,721,000114,400,000134,225,00076,021,000109,778,00094,180,00073,428,00071,936,00067,529,00089,168,00074,513,000105,300,00092,875,000132,369,00076,219,00050,852,000
Dividend
Jun 06, 20240.72 TWD/sh

Profile

Abnova (Taiwan) Corporation manufactures and sells various recombinant proteins and antibodies. The company's products portfolio includes SARS-CoV/CoV-2, DNA and RNA, proteins/peptides, DNAxPab, beads/dyes, lysates/slides, antibody pairs/kits, antibody and tissue arrays, in situ hybridization products, systems and automations, GMP and analyte specific reagents, and in vitro diagnostics. It also provides MaxPab, monoclonal, polyclonal, recombinant, conjugate, secondary/tag, IHC/pathology, and circulating rare cell antibodies. In addition, the company offers integrated solutions and services, including gene synthesis and cytogenetics; peptide services, protein expression, and conjugations; antibody production; and assay development services. Abnova (Taiwan) Corporation is headquartered in Taipei, Taiwan.
URL
https://www.abnova.com/
IPO date
May 27, 2008
Employees
Domiciled in
TW
Incorporated in
TW

Valuation

Title
TWD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
355,257
-7.01%
382,052
-7.21%
411,756
-8.80%
Cost of revenue
321,674
337,911
346,632
Unusual Expense (Income)
NOPBT
33,583
44,141
65,124
NOPBT Margin
9.45%
11.55%
15.82%
Operating Taxes
11,582
4,839
20,113
Tax Rate
34.49%
10.96%
30.88%
NOPAT
22,001
39,302
45,011
Net income
61,607
41.05%
43,678
-41.64%
74,843
163.82%
Dividends
(43,598)
(48,443)
(27,855)
Dividend yield
2.36%
2.28%
1.11%
Proceeds from repurchase of equity
BB yield
Debt
Debt current
5,508
5,105
7,199
Long-term debt
42,504
10,307
14,571
Deferred revenue
Other long-term liabilities
427
438
526
Net debt
(400,533)
(408,354)
(345,845)
Cash flow
Cash from operating activities
50,852
76,219
132,369
CAPEX
(6,620)
(19,566)
(13,861)
Cash from investing activities
19,777
36,791
(13,371)
Cash from financing activities
(49,092)
(55,620)
(61,400)
FCF
(9,267)
96,878
(15,553)
Balance
Cash
448,545
423,515
367,914
Long term investments
251
(299)
Excess cash
430,782
404,663
347,027
Stockholders' equity
727,395
811,792
817,467
Invested Capital
903,051
889,800
954,321
ROIC
2.45%
4.26%
4.85%
ROCE
2.50%
3.40%
4.98%
EV
Common stock shares outstanding
62,360
60,632
60,664
Price
29.65
-15.53%
35.10
-14.81%
41.20
-5.40%
Market cap
1,848,974
-13.12%
2,128,183
-14.85%
2,499,357
-5.29%
EV
1,448,441
1,719,829
2,153,512
EBITDA
63,546
76,452
99,617
EV/EBITDA
22.79
22.50
21.62
Interest
118
142
152
Interest/NOPBT
0.35%
0.32%
0.23%